• 1
    Baciu A, Stratton K, Burke S, eds. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: The National Academy Press, 2007.
  • 2
    Committee for Medical Products for Human Use. Reflection Paper on Benefit-Risk Assessment Methods in Context of the Evaluation of Marketing Authorisation Applications of Medicinal Products for Human Use. London: European Medicines Agency, 2008.
  • 3
    Bender R, Blettner M. Calculating the “number needed to be exposed” with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol 2002;55:52530.
  • 4
    Schulzer M, Mancini GB. “Unqualified success” and “unmitigated failure”: number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol 1996;25:70412.
  • 5
    Riegelman R, Schroth WS. Adjusting the number needed to treat: incorporating adjustments for the utility and timing of benefits and harms. Med Decis Making 1993;13:24752.
  • 6
    Sinclair JC, Cook RJ, Guyatt GH, et al. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 2001;54:25362.
  • 7
    Willan AR, O'Brien BJ, Cook DJ. Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. Control Clin Trials 1997;18:12130.
  • 8
    Chuang-Stein C, Mohberg NR, Sinkula MS. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med 1991;10:134959.
  • 9
    Lynd LD, O'Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. J Clin Epidemiol 2004;57:795803.
  • 10
    Garrison LP, Jr., Towse A, Bresnahan BW. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood) 2007;26:68495.
  • 11
    Center for Drug Evaluation and Research. Lotronex tablets (alosetron hydrochloride): questions and answers. 2002. Available from:[Accessed December 4, 2007.
  • 12
    Krinsky I, Robb AL. On approximating the statistical properties of elasticities. MIT Press 1986;68:7159.
  • 13
    Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99:2195203.
    Direct Link:
  • 14
    Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101:106979.
    Direct Link:
  • 15
    Wolfe SG, Chey WY, Washington MK, et al. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol 2001;96:80311.
    Direct Link:
  • 16
    Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment Pharmacol Ther 2003;17:102130.
  • 17
    Drummond M, Sculpher M, Torrance G, et al. Methods for Economic Evalution of Health Programs. New York: Oxford University Press, 2005.
  • 18
    National Institute for Clinical Excellence. Guide to Methods of Technology Appraisal. London: National Health Service, 2004.
  • 19
    Hillner BE. Anastrozole had a better risk-benefit profile than tamoxifen as adjuvant treatment for breast cancer in postmenopausal women. ACP J Club 2007;146:4.
  • 20
    Hoffmann JN, Wiedermann CJ, Juers M, et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006;95:8506.
  • 21
    Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:81936.
  • 22
    Rodondi N, Bauer DC. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Am J Med 2004;117:52830.
  • 23
    Barie PS, Williams MD, McCollam JS, et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:21220.
  • 24
    Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003;145:38796.
  • 25
    Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ 2004;328:71.
  • 26
    US Food and Drug Administration. Transcript: joint meeting with the risk management subcommittee of the advisory committee for pharmaceutical sciences. 2002. Available from:[Accessed February 29, 2008.